Doxofylline

• CAT Number: A000626
• CAS Number: 69975-86-6
• Molecular Formula: C11H14N4O4
• Molecular Weight: 266.3
• Purity: ≥95%
• Target: Phosphodiesterase Inhibitor
• Storage: -20°C
• InChI: 1S/C11H14N4O4/c1-13-9-8(10(16)14(2)11(13)17)15(6-12-9)5-7-18-3-4-19-7/h6-7H,3-5H2,1-2H3
• InChIKey: HWXIGFIVGWUZAO-UHFFFAOYSA-N
• SMILES: CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC3OCCO3

Doxofylline (Cat. No: A000626), also known as Ansimar and ABC-12-3, is a novel xanthine bronchodilator. Doxofylline’s mechanism of action is related to the inhibition of phosphodiesterase activities, but it appears to have decreased affinities towards adenosine A1 and A2 receptors, which may account for its better safety profile.

Reference

1: Riffo-Vasquez Y, Venkatasamy R, Page CP. Steroid sparing effects of
doxofylline. Pulm Pharmacol Ther. 2017 Oct 12. pii: S1094-5539(17)30221-3. doi:
10.1016/j.pupt.2017.10.008. [Epub ahead of print] PubMed PMID: 29031617.

2: Sasi Rekha P, Gunasekaran S. A novel spectroscopic analysis to detect
photochemical reaction of the bronchodilator – Doxofylline and its estimation in
pharmaceutical formulation. Spectrochim Acta A Mol Biomol Spectrosc. 2018 Feb
5;190:140-149. doi: 10.1016/j.saa.2017.09.006. Epub 2017 Sep 11. PubMed PMID:
28922640.

3: Patel BS, Kugel MJ, Baehring G, Ammit AJ. Doxofylline does not increase
formoterol-induced cAMP nor MKP-1 expression in ASM cells resulting in lack of
anti-inflammatory effect. Pulm Pharmacol Ther. 2017 Aug;45:34-39. doi:
10.1016/j.pupt.2017.04.006. Epub 2017 Apr 13. PubMed PMID: 28414142.

4: Zhu P, Lu J, Hong L, Su W, Van Schepdael A, Adams E. Characterization of an
unknown impurity in doxofylline using LC-MS and NMR. J Pharm Biomed Anal. 2017
Jun 5;140:31-37. doi: 10.1016/j.jpba.2017.03.025. Epub 2017 Mar 18. PubMed PMID:
28340472.

5: Raju CK, Pandey AK, S G, Ghosh K, Pola A, Goud P SK, Jaywant MA, Navalgund SG.
Isolation and characterization of novel degradation products of Doxofylline using
HPLC, FTIR, LCMS and NMR. J Pharm Biomed Anal. 2017 Jun 5;140:1-10. doi:
10.1016/j.jpba.2017.02.044. Epub 2017 Mar 1. PubMed PMID: 28334552.

6: Zhang Y, Zeng K, Wang J, Gao H, Nan Y, Zheng X. Identifying the antiasthmatic
target of doxofylline using immobilized β2 -adrenoceptor based high-performance
affinity chromatography and site-directed molecular docking. J Mol Recognit. 2016
Oct;29(10):492-8. doi: 10.1002/jmr.2549. Epub 2016 May 12. PubMed PMID: 27173639.

7: Lal D, Manocha S, Ray A, Vijayan VK, Kumar R. Comparative study of the
efficacy and safety of theophylline and doxofylline in patients with bronchial
asthma and chronic obstructive pulmonary disease. J Basic Clin Physiol Pharmacol.
2015 Sep;26(5):443-51. doi: 10.1515/jbcpp-2015-0006. PubMed PMID: 25894641.

8: Rajanandh MG, Nageswari AD, Ilango K. Assessment of montelukast, doxofylline,
and tiotropium with budesonide for the treatment of asthma: which is the best
among the second-line treatment? A randomized trial. Clin Ther. 2015 Feb
1;37(2):418-26. doi: 10.1016/j.clinthera.2014.12.008. Epub 2015 Jan 8. PubMed
PMID: 25577543.

9: Rajanandh MG, Nageswari AD, Ilango K. Pulmonary function assessment in mild to
moderate persistent asthma patients receiving montelukast, doxofylline, and
tiotropium with budesonide: a randomized controlled study. Clin Ther. 2014 Apr
1;36(4):526-33. doi: 10.1016/j.clinthera.2014.02.006. Epub 2014 Mar 17. PubMed
PMID: 24650447.

10: Samanthula G, Yadiki K, Saladi S, Gutala S, Surendranath KV.
Stability-Indicating RP-HPLC Method for the Simultaneous Estimation of
Doxofylline and Terbutalinesulphate in Pharmaceutical Formulations. Sci Pharm.
2013 Jul 14;81(4):969-82. doi: 10.3797/scipharm.1305-14. Print 2013 Oct-Dec.
PubMed PMID: 24482767; PubMed Central PMCID: PMC3867251.